Avita Medical (ASX: AVH) received US Food and Drug Administration approval for its premarket approval supplement for the Recell Go mini, a disposable cartridge designed to treat smaller wounds up to 480 square centimeters, according to a Tuesday filing with the Australian bourse.

This extends the company's Recell Go platform, which previously handled larger wounds up to 1,920 square centimeters, the filing said.

The regenerative medicine company plans to roll out the product in the first quarter of 2025, targeting broader access to smaller wound care.